You are here

  • Home
  • Archive
  • Volume 103, Issue 13
  • Oral anticoagulation for elderly patients with non-valvular atrial fibrillation: recent insights from randomised trials and the ‘real world’

Article Text

Article menu
Download PDFPDF
Editorial
Oral anticoagulation for elderly patients with non-valvular atrial fibrillation: recent insights from randomised trials and the ‘real world’

https://doi.org/10.1136/heartjnl-2017-311162

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    Footnotes

    • Competing interests GYHL: Consultant for Bayer/Janssen, BMS/Pfizer, Biotronik, Medtronic, Boehringer Ingelheim, Microlife and Daiichi-Sankyo. Speaker for Bayer, BMS/Pfizer, Medtronic, Boehringer Ingelheim, Microlife, Roche and Daiichi-Sankyo No fees are received personally. Consultancy and speaker honoraria are received into a group private practice company.

    • Provenance and peer review Commissioned; internally peer reviewed.

    Linked Articles

    • Arrhythmias and sudden death
      Effects of dabigatran according to age in atrial fibrillation
      Mandy N Lauw John W Eikelboom Michiel Coppens Lars Wallentin Salim Yusuf Michael Ezekowitz Jonas Oldgren Juliet Nakamya Jia Wang Stuart J Connolly
      Heart 2017; 103 1015-1023 Published Online First: 17 Feb 2017. doi: 10.1136/heartjnl-2016-310358